Aeterna Zentaris Inc. (TSE:AEZS) has released an update.
Aeterna Zentaris Inc. reported a strong cash position of $29.5 million at the end of the first quarter of 2024, despite a net loss increase primarily due to decreased revenues and higher merger-related expenses. The company completed recruitment for its DETECT-trial and anticipates trial completion and data release in 2024, alongside the expected closure of an all-stock merger with Ceapro Inc. in the second quarter. These developments mark an exciting period for Aeterna as it continues to advance its pharmaceutical and diagnostic products portfolio.
For further insights into TSE:AEZS stock, check out TipRanks’ Stock Analysis page.
